Sirona Biochem Corporate Update January 2024

Article content material

VANCOUVER, British Columbia, Jan. 24, 2024 (GLOBE NEWSWIRE) — Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) supplies the next replace:

Pricey shareholders,

Article content material

We’re happy to supply an replace on our latest milestones and strategic choices shaping Sirona Biochem’s path ahead.

Trademark of TFC-1326 as GlycoProteMim

We not too long ago trademarked TFC-1326 as GlycoProteMim^TM. This branding determination goals to differentiate our anti-aging lively ingredient in a aggressive market by giving it an simply recognizable identification, whereas additionally enhancing its marketability and positioning it as a sought-after answer within the magnificence business. With a various array of choices for customers to handle seen indicators of growing old, our model goals to be one that folks may be educated about, understanding its advantages and simply figuring out it within the market.

Article content material

Institution of Sirona Laboratories

We’re excited to introduce Sirona Laboratories^TM, a newly established entity devoted to commercializing GlycoProteMim. This determination is rooted in our dedication to expedite the commercialization course of and supply a streamlined avenue for market penetration.

Sirona Biochem will keep majority possession within the subsidiary. This may guarantee a extra streamlined and environment friendly commercialization course of by eliminating the frequent delays related to exterior partnerships. We’re poised to convey this revolutionary skincare answer to market within the shortest time doable.

In the end, the creation of Sirona Laboratories stands as a strategic transfer that immediately advantages our stakeholders. It not solely safeguards shareholder pursuits but in addition positions GlycoProteMim as a useful asset inside a separate entity, presenting potential avenues for capitalization on its know-how whereas preserving the integrity of Sirona Biochem.

Within the aesthetic house model acquisitions at excessive valuations are frequent and novel know-how optimally capitalized when a part of a longtime model. Magnificence model M&A is predicted to be a rising market development. https://www.beautyindependent.com/kearney-predicts-beauty-ma-activity-increase/.

Article content material

Article content material

Preparation for commercialization of GlycoProteMim

Closing course of improvement for the manufacturing of GlycoProteMim by Wuxi AppTec has been accomplished and they’re prepared to provide multi-kilogram orders upon request. Work is properly underway on a number of different fronts obligatory to provide a top quality client product. Additional updates might be made close to time period relating to the crew of consultants we’re assembling for this activity.

It’s our intention to launch our first client product containing GlycoProteMim in each Europe and North America via our subsidiary Sirona Laboratories, then increasing to different markets globally. With the required funding, we have now set out a plan to launch our first product early within the 1^st quarter of 2024. The elemental science is clinically confirmed, and security established so the work wanted is principally to fulfill technical necessities of a brand new product and re-establish its effectiveness obligatory to permit applicable product claims.

TFC-1067 – World Licensing Settlement with Allergan Aesthetics

Allergan continues to work towards integration of TFC-1067 into its pipeline. As soon as permissible, we are going to replace our shareholders accordingly. Sirona’s administration stays in common communication with Allergan Anesthetic’s crew.

Article content material

Antiviral Library, Diabetes and different new R&D tasks

TFChem’s scientists at Sirona are actively concerned in progressing the antiviral and SGLT 2 diabetic undertaking. Regardless of this ongoing effort, these tasks usually are not at the moment the highest precedence. The first focus of the crew is directed in the direction of pioneering new developments throughout the aesthetic house. It’s price noting that sure points of their work are stored confidential till they attain a stage the place mental property (IP) may be securely established.

Making Sirona Laboratories a Market Success

To materialize the success of GlycoProteMim, we might be securing strategic funding from personal fairness funds and buyers. This infusion of considerable upfront capital is earmarked for essential points corresponding to stock, retail infrastructure, and impactful advertising and marketing efforts, which can all contribute to a sturdy and profitable product launch.

Envisioning past a single product, Sirona Biochem sees a way forward for diversified choices with a number of merchandise using GlycoProteMim. Preserving shareholder worth is a core precept in our technique. By avoiding vital dilution and management points, we be certain that our shareholders get pleasure from a considerable portion of the income stream generated by GlycoProteMim.

Article content material

Different Worthwhile Markets

Past GlycoProteMim, we will proceed to advance tasks in areas corresponding to Cellulite, Wound care, and Keloid therapies, underscoring our dedication to complete skincare options. Sirona Laboratories is poised to convey to market not solely GlycoProteMim but in addition new cosmeceuticals developed by TFChem. This collaboration enhances our potential to introduce a various and big selection of revolutionary skincare options.

By pursuing a faster path to profitability, we scale back reliance on recurrent financing, making certain stability and a sustainable development trajectory for Sirona Biochem and its subsidiaries. Sirona Biochem’s steady monetary supply paves the best way for bringing quite a few backlogged concepts from our scientific crew into industrial actuality. This proactive method to innovation ensures that our pipeline stays dynamic and attentive to rising skincare wants.

About Sirona Biochem Corp.

Sirona Biochem is a beauty ingredient and drug discovery firm with proprietary platform know-how. Sirona makes a speciality of stabilizing carbohydrate molecules with the aim of enhancing efficacy and security. New compounds are patented for optimum income potential.

Article content material

Sirona’s compounds are licensed to main corporations world wide in return for licensing charges, milestone charges, and ongoing royalty funds. Sirona’s laboratory, TFChem, is positioned an hour north of Paris, France, and is the recipient of a number of French nationwide scientific awards and European Union and French authorities grants. For extra info, please go to www.sironabiochem.com.

For extra info relating to this press launch, please contact:

Investor Enquiries:
Electronic mail: Data@sironabiochem.com
Christopher Hopton, CFO, 778-908-4734

Neither TSX Enterprise Change nor its Regulation Providers Supplier (as that time period is outlined in insurance policies of the TSX Enterprise Change) accepts duty for the adequacy or accuracy of this launch.

______________________________

Sirona Biochem cautions you that statements included on this press launch that aren’t an outline of historic info could also be forward-looking statements. Ahead-looking statements are solely predictions primarily based upon present expectations and contain identified and unknown dangers and uncertainties. You might be cautioned to not place undue reliance on these forward-looking statements, which converse solely as of the date of launch of the related info, until explicitly acknowledged in any other case. Precise outcomes, efficiency or achievement may differ materially from these expressed in, or implied by, Sirona Biochem’s forward-looking statements as a result of dangers and uncertainties inherent in Sirona Biochem’s enterprise together with, with out limitation, statements about: the progress and timing of its medical trials; difficulties or delays in improvement, testing, acquiring regulatory approval, producing and advertising and marketing its merchandise; sudden antagonistic unintended effects or insufficient therapeutic efficacy of its merchandise that might delay or stop product improvement or commercialization; the scope and validity of patent safety for its merchandise; competitors from different pharmaceutical or biotechnology corporations; and its potential to acquire extra financing to assist its operations. Sirona Biochem doesn’t assume any obligation to replace any forward-looking statements besides as required by regulation.

Article content material